93434-59-4

Basic information

• Product Name: Benzenepropanoic acid, a-hydroxy-, phenylmethyl ester
• CAS NO: 93434-59-4
• Molecular Formula: C16H16O3
• Molecular Weight: 256.301
• Mol File: 93434-59-4.mol
• Article Data: 18

Chemical Properties

• CAS DataBase Reference: Benzenepropanoic acid, a-hydroxy-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenepropanoic acid, a-hydroxy-, phenylmethyl ester(93434-59-4)
• EPA Substance Registry System: Benzenepropanoic acid, a-hydroxy-, phenylmethyl ester(93434-59-4)

Safety Data

• Hazardous Substances Data: 93434-59-4(Hazardous Substances Data)

Upstream product

• 828-01-3 D-phenyllactic acid 
• 100-39-0 benzyl bromide 
• 100-51-6 benzyl alcohol 
• 673-06-3 D-(R)-phenylalanine 
• 103-41-3 benzy cinnamate 
• 828-01-3 phenyllactic acid 

Downstream Products

• 7622-21-1 (R)-benzyl mandelate 
• 212117-43-6 (S)-2-{(R)-3-[(S)-2-(tert-Butoxycarbonyl-methyl-amino)-4-methyl-pentanoyloxy]-2-oxo-azepan-1-yl}-4-methyl-pentanoic acid (R)-1-benzyloxycarbonyl-2-phenyl-ethyl ester 
• 903881-52-7 benzyl (S)-2-(3'-bromophenoxy)-3-phenylpropanoate 
• 7622-21-1 benzyl-(S)-(-)-2-hydroxy-3-phenylpropionate 
• 1360455-37-3 Fmoc-L-MeLeu-D-PhLac-OH 
• 1370598-41-6 Fmoc-L-MeLeu-D-PhLac-OBn 
• 950493-29-5 benzyl (2S)-2-{[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]oxy}-3-phenylpropanoate 
• 931119-57-2 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yloxy)-3-phenyl-propionic acid benzyl ester 
• 882069-81-0 (S)-2-{2-methyl-4-[2,2,2-trifluoro-1-(4-methoxy-benzyloxy)-1-trifluoromethyl-ethyl]-phenoxy}-3-phenyl-propionic acid benzyl ester 
• 115406-23-0 N-[N-(1(S)-carboxyl-3-phenylpropyl)-(S)-phenylalanyl]-(R)-isoserine 

Relevant articles and documents

Selective Monovalent Galectin-8 Ligands Based on 3-Lactoylgalactoside

Galectin-8 has gained attention as a potential new pharmacological target for the treatment of various diseases, including cancer, inflammation, and disorders associated with bone mass reduction. To that end, new molecular probes are needed in order to better understand its role and its functions. Herein we aimed to improve the affinity and target selectivity of a recently published galectin-8 ligand, 3-O-[1-carboxyethyl]-β-d-galactopyranoside, by introducing modifications at positions 1 and 3 of the galactose. Affinity data measured by fluorescence polarization show that the most potent compound reached a KD of 12 μM. Furthermore, reasonable selectivity versus other galectins was achieved, making the highlighted compound a promising lead for the development of new selective and potent ligands for galectin-8 as molecular probes to examine the protein's role in cell-based and in vivo studies.

ENDOPARASITIC DEPSIPEPTIDES

The present invention provides cyclic depsipeptides of Formula (1), stereoisomers thereof, and veterinary acceptable salts thereof wherein each of R1, R2, R3, R4, L1, and L2 are as defined herein. The present invention also contemplates compositions, methods of treatment, and uses as a medicament to treat an animal for an endoparasitic infection with a Formula (1 ) compound.

Total synthesis of the cyclic depsipeptide YM-280193, a platelet aggregation inhibitor

The first total synthesis of YM-280193, a cyclic depsipeptide that inhibits the ADP-induced aggregation of human platelets, is described. The monomer and dipeptide fragments were prepared using conventional chemistry and subsequently assembled by Fmoc-solid-phase peptide synthesis (Fmoc-SPPS). A late-stage novel bis-alkylation-elimination of cysteine on-resin was employed to introduce the unnatural N-methyldehydroalanine moiety. The final step involved execution of a key macrolactamization reaction between the hindered unnatural N,O-dimethylthreonine and ?2-hydroxyleucine residues.